Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Pruebas genómicas de recurrencia en cáncer de mama - OncotypeDx y su entornoMauricio Lema
Presentación para el simposio satélite de Amarey en el marco del congreso de los 85 años del Instituto Nacional de Cancerología, Hotel Hyatt, 29.08.2019, Bogotá
Recent advancements in metastatic colorectal cancer treatmentKindai University
In this presentation, the presenter tries to provide an overview of the current established treatment strategies, based on their clinical outcomes as well as their mechanisms, limitations that remain to be overcome, and their future applicability for the treatment of human Colorectal Cancer.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
advancements in the diagnostics help detect states like oligometastasis ,which can lead to selection of patients for local and MDT and prolong the time to adjuvant therapy, at present There is no consensus on the treatment of oligometastatic cancer and clinical trials can help in evidence formation.
Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC):
Pruebas genómicas de recurrencia en cáncer de mama - OncotypeDx y su entornoMauricio Lema
Presentación para el simposio satélite de Amarey en el marco del congreso de los 85 años del Instituto Nacional de Cancerología, Hotel Hyatt, 29.08.2019, Bogotá
Recent advancements in metastatic colorectal cancer treatmentKindai University
In this presentation, the presenter tries to provide an overview of the current established treatment strategies, based on their clinical outcomes as well as their mechanisms, limitations that remain to be overcome, and their future applicability for the treatment of human Colorectal Cancer.
Overview about evolution of the term Oligometastases,the paradigm and various states of oligometastases,treat options ,clinical trials and relevance in current clinical practice
advancements in the diagnostics help detect states like oligometastasis ,which can lead to selection of patients for local and MDT and prolong the time to adjuvant therapy, at present There is no consensus on the treatment of oligometastatic cancer and clinical trials can help in evidence formation.
15. 正解はどれでしょうか?
2020/12/14 Division of Medical Oncology, Nippon Medical School Musashikosugi Hospital
集団に対してある癌の検診を行った
検診後に観察された変化の中で、検診が有効であったことを
示す根拠はどれか
a 検診で発見されたその癌の患者数の増加
b 検診で発見されたその癌の患者の生存率の上昇
c 集団全体におけるその癌の死亡率の低下
d 集団全体におけるその癌の罹患率の低下
e 検診に用いられた検査の陽性反応適中率の上昇
第106回(2012年)医師国家試験問題より。
16. Choosing Wisely in Japan
1. 健康で無症状の人々に対してPET-CT検査によるがん検診プログラムを推奨
しない
2. 健康で無症状の人々に対して血清CEAなどの腫瘍マーカー検査によるがん
検診を推奨しない
3. 健康で無症状の人々に対してMRI 検査による脳ドック検査を推奨しない
4. 自然軽快するような非特異的な腹痛でのルーチンの腹部CT検査を推奨しな
い
5. 臨床的に適用のないル-チンの尿道バルーンカテーテルの留置を推奨しな
い
Division of Medical Oncology, Nippon Medical School Musashikosugi Hospital
総合診療指導医コンソーシアム
General Medicine. 2015; 16: 3-4
21. 日本 vs 米国 検診推奨度の違い
対象部位 対象者 検診の方法
推奨
グレード
USPSTFの推奨グレード
胃がん 50歳以上男女
胃X線検査 B -
胃内視鏡検査 B -
ヘリコバクターピロリ抗体 I -
大腸が
ん
40歳以上男女
便潜血検査 A A (50~75歳)
S状結腸内視鏡検査 C A (50~75歳)
全大腸内視鏡検査 C A (50~75歳)
注腸X線検査 C -
肺がん 40歳以上男女
非高危険群に胸部X線検査、及び高危険
群に胸部X線検査と喀痰細胞診
B D
低線量CT I B (55-80歳高危険群)
子宮頸
がん
20歳以上女
細胞診(従来法) B
細胞診 A (21-65歳)
細胞診+ HPV検査(30-65歳)
細胞診(液状検体法) B
HPV検査を含む方法*11 I
乳がん
40-74歳 マンモグラフィ単独 B B (50-74歳)
40-64歳 マンモグラフィ+視触診 B -
40歳未満 マンモグラフィ単独法±視触診 I C (50歳未満)
全年齢 視触診 I D
全年齢 超音波検査 I -
国立がん研究センターがん予防・検診研究センター2016, USPSTF (U.S. Preventive Services Task Force)